5.1 Enteral Nutrition: Access, Indications, & Formula Selection

5.1 Enteral Nutrition: Access, Indications, & Formula Selection

Quick Summary: Enteral nutrition (EN) is the preferred route of nutrition support for oncology patients who possess a functional gastrointestinal (GI) tract but are unable to maintain adequate oral intake (<60% of needs for >7–14 days). Enteral access selection is governed by anticipated duration (<4–6 weeks for nasoenteric tubes vs. >4–6 weeks for percutaneous enterostomies) and aspiration risk or surgical anatomy. Formula selection ranges from standard polymeric (1.0–1.5 kcal/mL) to semi-elemental/peptide formulas for intestinal malabsorption and concentrated 2.0 kcal/mL formulas for fluid overload.

Clinical Guidelines and Indications for EN

Enteral nutrition (EN) represents the primary therapeutic modality for oncology patients who possess a functionally intact gastrointestinal tract but are unable to maintain adequate oral intake to meet metabolic demands. According to joint clinical guidelines from the American Society for Parenteral and Enteral Nutrition (ASPEN), the European Society for Clinical Nutrition and Metabolism (ESPEN), and the National Comprehensive Cancer Network (NCCN), enteral nutrition support must be initiated when an oncology patient cannot ingest at least 60% of estimated energy requirements for more than 7 to 14 days, or when severe head and neck or upper GI mechanical obstruction renders oral intake impossible.

Maintaining enteral stimulation preserves the gut mucosal barrier integrity, prevents bacterial translocation from gut-associated lymphoid tissue (GALT) atrophy, maintains splanchnic blood flow, and significantly reduces infectious complications and hospital length of stay compared to parenteral nutrition (PN).

Clinical Indications & Contraindications Matrix

---

Enteral Access Routes & Selection Criteria

Choosing the correct access route depends on the anticipated duration of feeding, aspiration risk, and gastrointestinal anatomy (especially post-surgical alterations such as gastrectomy or esophagectomy).

---

Enteral Formula Selection Matrix

Formulas are categorized based on protein structure, osmolality, caloric density, and specialized lipid or fiber content:

1. Standard Polymeric Formulas (1.0 – 1.5 kcal/mL)

• Composition: Intact proteins (casein, whey, soy protein isolate), complex carbohydrates (maltodextrin), and long-chain triglycerides (LCTs).
• Indications: Oncology patients with normal digestive and absorptive capacity.
• Protein Distribution: Standard (14–18% total energy) or High-Protein (20–25% total energy) to meet oncology protein requirements (1.2–2.0 g/kg/day).

2. Nutrient-Dense / Concentrated Formulas (1.8 – 2.0 kcal/mL)

• Composition: High caloric density with reduced free water (~70–71% free water by volume).
• Indications: Patients requiring strict volume restriction due to congestive heart failure, severe ascites, renal failure, or profound early satiety.

3. Semi-Elemental / Peptide-Based Formulas (1.0 – 1.5 kcal/mL)

• Composition: Hydrolyzed whey/casein proteins (di- and tri-peptides), free amino acids, maltodextrin, and a high proportion of Medium-Chain Triglycerides (MCTs, 40–70% of total fat).
• Indications: Radiation enteritis, pancreatic exocrine insufficiency (PEI), short bowel syndrome, severe malabsorption, chylous leaks, or failure of polymeric formulas.
• Mechanism: MCTs are absorbed directly into portal venous circulation without requiring pancreatic lipase or bile salt micellar solubilization. Di- and tri-peptides utilize intestinal PEPT1 mucosal transporters, which remain functional during radiation mucosal injury.

4. Immune-Modulating Formulas

• Composition: Supplemental L-arginine, omega-3 fatty acids (EPA/DHA), RNA nucleotides, and antioxidants.
• Indications: Perioperative surgical oncology candidates (gastrointestinal and head & neck resections). ASPEN/ESPEN recommends 5 to 7 days pre-operatively in malnourished surgical candidates to reduce post-operative infectious complications and surgical site infections.

---

Administration Methods & Infusion Schedules

1. Continuous Infusion: Delivered via volumetric enteral pump over 24 hours. Mandatory for small bowel (jejunal) feeding to prevent abdominal cramps, diarrhea, and hyperosmolar volume overload. Recommended during initiation in malnourished patients.
2. Cyclic Nocturnal Infusion: Delivered via pump over 12 to 16 hours, typically overnight. Ideal for ambulatory oncology patients recovering oral intake, allowing daytime freedom from feeding pumps.
3. Gravity Drip Infusion: Administered over 30 to 60 minutes per feeding bag, 4 to 6 times daily into the stomach.
4. Syringe Bolus Infusion: 200 to 400 mL administered over 15 to 30 minutes 4 to 6 times daily into the stomach. Mimics normal meal patterns. Strictly contraindicated for small bowel (jejunal) access.

---

Worked Example: Enteral Nutrition Prescription Calculation

Patient Scenario

A 62-year-old male with locally advanced head and neck cancer (weight: 70 kg, height: 175 cm, estimated needs: 2,100 kcal/day [30 kcal/kg] and 105 g protein/day [1.5 g/kg]) is placed on a high-protein polymeric formula (1.5 kcal/mL, 63 g protein/L, 76% free water).

Step 1: Calculate Formula Volume to Meet Energy Needs

$\text{Target Volume} = \frac{2,100 \text{ kcal}}{1.5 \text{ kcal/mL}} = 1,400 \text{ mL/day}$

Step 2: Verify Protein Delivery

$\text{Protein Delivered} = 1.4 \text{ L} \times 63 \text{ g/L} = 88.2 \text{ g protein}$ Deficit: $105 \text{ g} - 88.2 \text{ g} = 16.8 \text{ g protein deficit}$. Add 1.5 modular protein packets (15–18 g protein) daily to achieve target.

Step 3: Calculate Free Water Delivery and Flush Deficit

• Free Water from Formula: $1,400 \text{ mL} \times 0.76 = 1,064 \text{ mL free water}$.
• Total Fluid Goal (35 mL/kg): $70 \text{ kg} \times 35 \text{ mL/kg} = 2,450 \text{ mL/day}$.
• Supplemental Water Flush Deficit: $2,450 \text{ mL} - 1,064 \text{ mL} = 1,386 \text{ mL water/day}$.
• Water Flush Schedule: Administer 230 mL water flushes every 4 hours (6 times daily).

---

Monitoring & Complication Management

• Gastric Residual Volume (GRV): Routine GRV measurement is no longer recommended by ASPEN guidelines unless signs of GI intolerance (vomiting, abdominal distension) are present. GRV thresholds <500 mL should not prompt automatic EN holding.
• Tube Patency & Water Flushes: Flush tubes with 30–50 mL of warm water every 4 hours during continuous feeding, and before/after medication administration.
• Declogging Protocol: Never use carbonated beverages or meat tenderizers (can precipitate proteins). Use warm water flushes or an enzyme declogging kit containing sodium bicarbonate and pancreatic enzymes.